Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
12,705
Total Claims
$934K
Drug Cost
681
Beneficiaries
$1,371
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+62%
Opioid rate vs peers
4.2% vs 2.6% avg
+28%
Cost per patient vs peers
$1,371 vs $1,068 avg
+39%
Brand preference vs peers
12.5% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
4.2%
Opioid Rate
532
Opioid Claims
$8,240
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,574 claims · $752K
Generic: 10,974 claims · $170K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 149 | $121K |
| Empagliflozin | 119 | $88K |
| Fluticasone/Umeclidin/Vilanter | 108 | $77K |
| Dulaglutide | 56 | $63K |
| Rivaroxaban | 29 | $33K |
| Insulin Glargine,hum.Rec.Anlog | 39 | $30K |
| Sacubitril/Valsartan | 35 | $24K |
| Insulin Nph Hum/Reg Insulin Hm | 45 | $22K |
| Umeclidinium Brm/Vilanterol Tr | 30 | $18K |
| Insulin Nph Hum/Reg Insulin Hm | 49 | $17K |
| Insulin Detemir | 17 | $15K |
| Dapagliflozin Propanediol | 17 | $15K |
| Budesonide/Formoterol Fumarate | 30 | $14K |
| Insulin Nph Hum/Reg Insulin Hm | 15 | $14K |
| Sitagliptin Phosphate | 17 | $12K |
Prescribing Profile
Patient Profile
72
Avg Age
56%
Female
1.95
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data